Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENTURA-2: Aticaprant as Adjunctive Therapy in MDD with Anhedonia
NCT05550532Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of aticaprant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Dec 2022; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05550532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550532.